Immuneel Therapeutics Awarded $150,000 G-Rex Grant to Enhance CAR-T Cell Manufacturing in India through Bio-Techne's Collaborative Program

Reuters
10 Jun
Immuneel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Awarded $150,000 G-Rex Grant to Enhance CAR-T Cell Manufacturing in India through Bio-Techne's Collaborative Program

Bio-Techne Corporation, in collaboration with ScaleReady, Wilson Wolf Manufacturing, and CellReady, has announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant. This funding is part of a broader initiative aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. The grant will support Immuneel's process development, validation, and comparability studies at their state-of-the-art GMP facility in Bengaluru. This initiative is part of ScaleReady's G-Rex Grant Program, which has increased its total award funds to $30 million. The program has already awarded 200 grants, with each recipient eligible for up to $300,000 and access to exclusive support from a consortium of G-Rex Grant Partners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG99006) on June 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10